Raymed Labs Ltd Financials
Company Logo

Raymed Labs Ltd Financial Statement

Raymed Labs Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
RevenueTBA
Operating Expense0.02
Net Profit-0.02
Net Profit MarginTBA
Earning Per Share-0.04
EBIDTA-0.02
Effective Tax RateTBA

Raymed Labs Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue AnnualTBA
Operating Expenses Annual0.10
Operating Profit Annual-0.10
Interest AnnualTBA
Depreciation0.00
Net Profit Annual-0.10
Tax AnnualTBA

Raymed Labs Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the BeginningTBA
Cash Flow from Operations-0.06
Cash Flow from Investing0.06
Cash Flow from FinancingTBA
Cash Flow at the EndTBA

Raymed Labs Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)TBA
PBIT Margin (%)TBA
PBT Margin (%)TBA
Net PROFIT Margin (%)TBA
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)TBA
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)TBA

Raymed Labs Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual0.15
Total Current Assets Annual0.01
Non Current Assets Annual0.15
Total Shareholders Funds Annual-2.41
Total Assets Annual0.15

Raymed Labs Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Sep 19, 2024, Raymed Labs Ltd has a market capitalization of 0.93 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Raymed Labs Ltd is debt-free with a debt-to-equity ratio of 0.00.
In FY 2023 , Raymed Labs Ltd recorded a total revenue of approximately 0 Cr marking a significant milestone in the company's financial performance.
Raymed Labs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and NaN% annually, respectively..
Raymed Labs Ltd's current PE ratio is -9.30.
Raymed Labs Ltd's ROCE averaged -265.3% from the FY ending March 2022 to 2024, with a median of -262.5%. It peaked at -113.4% in March 2022, reflecting strong capital efficiency over the period..
Raymed Labs Ltd's latest EBIT is Rs. -0.10 Cr, surpassing the average EBIT of Rs. -0.12 Cr over the 5 years..